Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy
about
Aldosterone antagonists for preventing the progression of chronic kidney diseaseRecent advances in managing and understanding diabetic nephropathyDrug Targets for Oxidative Podocyte Injury in Diabetic NephropathyPresent and future in the treatment of diabetic kidney diseaseMineralocorticoid receptor blockade in chronic kidney diseaseAntihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone systemTherapeutic targeting of aldosterone: a novel approach to the treatment of glomerular diseaseTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.Diabetic kidney disease: a report from an ADA Consensus ConferenceAldosterone synthase inhibition in humansDiabetic kidney disease: from physiology to therapeuticsIs there a new dawn for selective mineralocorticoid receptor antagonism?Improvements in the Management of Diabetic NephropathyAS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathwayDiabetic nephropathy - Epidemiology in Asia and the current state of treatmentManagement of Diabetic Nephropathy in the Elderly: Special Considerations.Clinical therapeutic strategies for early stage of diabetic kidney disease.Long-term effects of spironolactone in peritoneal dialysis patientsData and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.The impact of antihypertensives on kidney disease.Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis.Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.Mineralocorticoid receptor antagonists and the metabolic syndromeComparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic ratsAdvances in treatment of hyperkalemia in chronic kidney disease.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of ACE (I/D) Gene Polymorphism in Type 2 Diabetic Population from Kutch RegionAldosterone and glomerular filtration--observations in the general populationNew insight into the molecular drug target of diabetic nephropathy.Inhibition of RAS in diabetic nephropathy.Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis.Epigenetics in diabetic kidney disease.Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con ViewThe kidney in type 2 diabetes therapyThe use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.A method for isolation and identification of urinary biomarkers in patients with diabetic nephropathy.Hypertension Management in Diabetic Kidney Disease
P2860
Q24194979-1E1A1A47-41A0-4A4E-87E0-556A433D2648Q26745900-1EAABB07-11BA-41FB-94B9-1FA203CC77CDQ26769787-D6D507CA-D22B-4771-86D0-2D8BEC306628Q26864133-4D8EA973-7F59-440B-9C62-AD5A4CC9937BQ26864370-F6523FAB-0540-4E05-9D58-8C7B1BFBBDFAQ26865691-AF373E19-6888-40AC-9AC7-909FF0276064Q26996385-4E95F574-E72D-4431-A224-160632B27C77Q27007027-666430BB-D5FA-4FF2-87EE-BA3B3336045AQ27012546-E705EB4A-B0AA-4E67-8F36-39139FCB2416Q27016157-BA2E0F79-B6BF-4DD3-8292-AE49955F2404Q27021392-2B05FA18-9DFE-4DE7-8DA4-E896468902D4Q27027792-776B0239-3B47-4D5B-9A0B-A0445D3FD67FQ28080717-6329C509-1AA4-4628-B854-7F4102BD7D05Q28542507-F0A1CEFA-DEFF-4E57-82CE-6700E0EB8490Q28742785-B162EA36-9265-4CB7-BF9A-3B43D70F1C13Q30353386-C0B807CA-09AA-40EB-BE75-44CF8A7B9B2DQ30363683-8CAF53D6-700E-4DF6-900B-81B588AB613DQ30413119-1F723EE6-F263-4894-9F00-5CD8BFF8E6FDQ31143932-E289DECD-CD73-4CB9-93B4-36C38308AA95Q33632021-D8606253-9E89-4C5F-9680-7CF7DDF3D769Q33734806-88E6CB4D-B4E3-44C7-856D-9CA070B2444BQ34071671-2A7DA52F-7460-402A-B415-5780A6313359Q34168923-803BA429-AF2C-42C6-BADE-254CB88BBA87Q34380070-BB783C82-3ECB-40EB-A71E-06BC55676798Q34450762-6AD1C3F4-27A7-4AAF-8ED6-6274EACA689EQ34491934-9B847C06-0D55-4DD6-9AA4-02852D2B0D70Q34604473-18D9D1AE-88B3-490B-AA89-B51ACAC6E334Q35028043-3737A556-960D-4413-A815-7A9E7E6214B5Q35115799-18842BC4-0DE5-4582-9329-5921C5C3900AQ35125585-B447E3EB-D5DE-4A2D-A234-D250BC11AF4BQ35491275-6FE4DFF7-58DD-45F3-B3C5-1B451097CFF6Q35546994-6B6C44C7-76F5-4438-B486-87075668F26DQ35557410-9D87838B-B0DA-461B-A1A5-53C00C49FBA1Q35647853-51846C44-534E-47E2-B894-FFA651FD4995Q35682234-78BC5C63-2A3E-4449-B559-74EA001B5A17Q35760302-43EBD2BC-8279-40B5-AB69-12D22266C976Q35834925-27B78711-D553-4691-97ED-D16E079743DCQ35883217-E5EB8875-D907-4BFC-BCDD-745D58370C55Q35896647-B5261666-B465-4DFB-93E8-B9C6E539DF26Q35953909-42740FD5-CD78-4D6E-AB3A-256BEEB880C5
P2860
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Addition of angiotensin recept ...... bition in diabetic nephropathy
@ast
Addition of angiotensin recept ...... bition in diabetic nephropathy
@en
Addition of angiotensin recept ...... bition in diabetic nephropathy
@nl
type
label
Addition of angiotensin recept ...... bition in diabetic nephropathy
@ast
Addition of angiotensin recept ...... bition in diabetic nephropathy
@en
Addition of angiotensin recept ...... bition in diabetic nephropathy
@nl
prefLabel
Addition of angiotensin recept ...... bition in diabetic nephropathy
@ast
Addition of angiotensin recept ...... bition in diabetic nephropathy
@en
Addition of angiotensin recept ...... bition in diabetic nephropathy
@nl
P2093
P2860
P3181
P356
P1476
Addition of angiotensin recept ...... bition in diabetic nephropathy
@en
P2093
Beverley Adams-Huet
Gloria L Vega
Philip Raskin
Robert D Toto
Uzma F Mehdi
P2860
P304
P3181
P356
10.1681/ASN.2009070737
P407
P577
2009-12-01T00:00:00Z